Diseases, Conditions, Syndromes

FDA approves mavyret for children, adolescents with hep C

(HealthDay)—Mavyret (glecaprevir and pibrentasvir) tablets are now approved to treat all six genotypes of hepatitis C virus (HCV) in children ages 12 to 17 years, the U.S. Food and Drug Administration announced yesterday.

Medications

Daclatasvir for hepatitis C: Added benefit not proven

The drug daclatasvir (trade name Daklinza) has been available since August 2014 for the treatment of adults with chronic hepatitis C (CHC) infection. The German Institute for Quality and Efficiency in Health Care (IQWiG) ...

Diseases, Conditions, Syndromes

How to achieve a functional cure for chronic hepatitis B

More than half of people with chronic hepatitis B have a form of the disease in which the immune system almost never achieves sustained control, despite many years of treatment. According to current knowledge, those affected ...

Diseases, Conditions, Syndromes

Predicting the outcome of hepatitis C virus treatment

Millions of people throughout the world are infected with hepatitis C virus (HCV), which can lead to cirrhosis of the liver and cancer. Directly acting antiviral agents inhibit viral proteins and have been used to successfully ...

Diseases, Conditions, Syndromes

Non-liver-related critical events down with SVR in HCV+Cirrhosis

(HealthDay)—For patients with hepatitis C virus (HCV) infection and biopsy-proven cirrhosis, sustained viral response (SVR) is associated with a reduction in critical events, both liver and non-liver related, according ...

Diseases, Conditions, Syndromes

Beginning of the end of hepatitis B in Australia?

(Medical Xpress)—A newborn vaccination program first introduced for Aboriginal babies in the Northern Territory has made significant inroads, significantly helping in the push to eradicate chronic hepatitis B infection ...

page 6 from 11